Payment overview · 2025
General Payments
$43.72
2 reported records · 2 companies
Healthcare provider profile · identity verified
Matthew Scott Payne, D.O
Allopathic & Osteopathic Physicians|Family Medicine · IDAHO FALLS, ID · NPI 1023246550
Verified facts
What the public records show
CMS Open Payments records show Matthew Scott Payne, D.O received $43.72 in general payments during 2025 across 2 reported records.
AstraZeneca Pharmaceuticals LP accounted for 69.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 2 associated products.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 18 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $30.23 | 69.1% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $13.49 | 30.9% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $43.72 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $30.23 | 1 | 2025 |
Source payment records
|
|||||
| General - Pain Management Normalized: general pain management |
Device | Boston Scientific Corporation | $13.49 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
18 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 611 | 151 |
| Levothyroxine Sodium | Levothyroxine Sodium | 507 | 118 |
| Omeprazole | Omeprazole | 469 | 106 |
| Losartan Potassium | Losartan Potassium | 423 | 110 |
| Metformin Hcl | Metformin Hcl | 390 | 95 |
| Gabapentin | Gabapentin | 367 | 86 |
| Amlodipine Besylate | Amlodipine Besylate | 341 | 84 |
| Lisinopril | Lisinopril | 282 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 250 | 68 |
| Simvastatin | Simvastatin | 215 | 51 |
| Tramadol Hcl | Tramadol Hcl | 213 | 49 |
| Trazodone Hcl | Trazodone Hcl | 207 | 57 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 205 | 72 |
| Tamsulosin Hcl | Tamsulosin Hcl | 188 | 52 |
| Furosemide | Furosemide | 175 | 52 |
| Eliquis | Apixaban | 174 | 38 |
| Montelukast Sodium | Montelukast Sodium | 174 | 44 |
| Sertraline Hcl | Sertraline Hcl | 172 | 37 |
| Alendronate Sodium | Alendronate Sodium | 163 | 42 |
| Potassium Chloride | Potassium Chloride | 160 | 48 |
| Prednisone | Prednisone | 157 | 48 |
| Metoprolol Succinate | Metoprolol Succinate | 153 | 34 |
| Famotidine | Famotidine | 150 | 28 |
| Pantoprazole Sodium | Pantoprazole Sodium | 147 | 37 |
| Bupropion Xl | Bupropion Hcl | 144 | 30 |
| Zolpidem Tartrate | Zolpidem Tartrate | 143 | 21 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 139 | 46 |
| Cephalexin | Cephalexin | 137 | 59 |
| Glipizide Er | Glipizide | 135 | 39 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 135 | 33 |
| Celecoxib | Celecoxib | 127 | 35 |
| Clonazepam | Clonazepam | 121 | 21 |
| Duloxetine Hcl | Duloxetine Hcl | 121 | 30 |
| Escitalopram Oxalate | Escitalopram Oxalate | 120 | 27 |
| Carvedilol | Carvedilol | 119 | 29 |
| Fluoxetine Hcl | Fluoxetine Hcl | 114 | 29 |
| Meloxicam | Meloxicam | 114 | 34 |
| Ozempic | Semaglutide | 114 | 20 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 111 | 34 |
| Lorazepam | Lorazepam | 109 | 23 |
| Alprazolam | Alprazolam | 108 | 22 |
| Tizanidine Hcl | Tizanidine Hcl | 105 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 104 | 40 |
| Metoprolol Tartrate | Metoprolol Tartrate | 102 | 29 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 101 | 25 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 95 | 47 |
| Allopurinol | Allopurinol | 89 | 22 |
| Amitriptyline Hcl | Amitriptyline Hcl | 88 | 21 |
| Mirtazapine | Mirtazapine | 87 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 84 | 38 |
| Donepezil Hcl | Donepezil Hcl | 82 | 25 |
| Pregabalin | Pregabalin | 78 | 12 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 74 | 18 |
| Citalopram Hbr | Citalopram Hydrobromide | 70 | 20 |
| Pravastatin Sodium | Pravastatin Sodium | 70 | 19 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 69 | 12 |
| Azithromycin | Azithromycin | 68 | 56 |
| Spironolactone | Spironolactone | 68 | 18 |
| Ibuprofen | Ibuprofen | 60 | 25 |
| Baclofen | Baclofen | 59 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 58 | 13 |
| Clonidine Hcl | Clonidine Hcl | 56 | 15 |
| Fluconazole | Fluconazole | 56 | 21 |
| Sucralfate | Sucralfate | 55 | 16 |
| Quetiapine Fumarate | Quetiapine Fumarate | 54 | 13 |
| Sumatriptan Succinate | Sumatriptan Succinate | 53 | 13 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 52 | 19 |
| Estradiol | Estradiol | 51 | 12 |
| Linzess | Linaclotide | 51 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 46 | 20 |
| Metformin Hcl Er | Metformin Hcl | 43 | 14 |
| Doxepin Hcl | Doxepin Hcl | 42 | suppressed |
| Nystatin | Nystatin | 42 | 25 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 42 | suppressed |
| Topiramate | Topiramate | 41 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 40 | 11 |
| Ventolin Hfa | Albuterol Sulfate | 40 | 13 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 20 |
| Gemfibrozil | Gemfibrozil | 38 | suppressed |
| Mounjaro | Tirzepatide | 38 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 38 | 13 |
| Trulicity | Dulaglutide | 37 | suppressed |
| Cefdinir | Cefdinir | 35 | 32 |
| Januvia | Sitagliptin Phosphate | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 35 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 33 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 32 | 20 |
| Lamotrigine | Lamotrigine | 31 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 31 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Torsemide | Torsemide | 30 | suppressed |
| Aripiprazole | Aripiprazole | 29 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 29 | 18 |
| Paroxetine Hcl | Paroxetine Hcl | 29 | 11 |
| Testosterone Cypionate | Testosterone Cypionate | 29 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 28 | suppressed |
| Ramipril | Ramipril | 28 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 28 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 27 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 27 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 27 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 26 | 11 |
| Lansoprazole | Lansoprazole | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 18 |
| Promethazine Hcl | Promethazine Hcl | 26 | suppressed |
| Temazepam | Temazepam | 26 | suppressed |
| Amoxicillin | Amoxicillin | 25 | 18 |
| Atenolol | Atenolol | 25 | suppressed |
| Glimepiride | Glimepiride | 25 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 24 | 15 |
| Fenofibrate | Fenofibrate | 24 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 24 | 11 |
| Primidone | Primidone | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 23 | 13 |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Chlorthalidone | Chlorthalidone | 22 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 22 | suppressed |
| Lovastatin | Lovastatin | 22 | suppressed |
| Terbinafine Hcl | Terbinafine Hcl | 22 | suppressed |
| Ezetimibe | Ezetimibe | 21 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 21 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 21 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 20 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 20 | suppressed |
| Diazepam | Diazepam | 19 | suppressed |
| Risperidone | Risperidone | 19 | suppressed |
| Acyclovir | Acyclovir | 18 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 18 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 18 | suppressed |
| Minocycline Hcl | Minocycline Hcl | 18 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Carbamazepine | Carbamazepine | 17 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 17 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 17 | suppressed |
| Finasteride | Finasteride | 17 | suppressed |
| Glipizide | Glipizide | 17 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 17 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 17 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 17 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 16 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 16 | suppressed |
| Permethrin | Permethrin | 16 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 15 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 15 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 15 | suppressed |
| Mupirocin | Mupirocin | 15 | 12 |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 14 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 14 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 13 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 13 | suppressed |
| Eszopiclone | Eszopiclone | 13 | suppressed |
| Humulin 70/30 Kwikpen | Insulin Nph Hum/Reg Insulin Hm | 13 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 13 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 13 | suppressed |
| Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Phenobarbital | Phenobarbital | 13 | suppressed |
| Sotalol | Sotalol Hcl | 13 | suppressed |
| Topiramate Er | Topiramate | 13 | suppressed |
| Zonisamide | Zonisamide | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Aspirin-Dipyridamole Er | Aspirin/Dipyridamole | 12 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 12 | suppressed |
| Desipramine Hcl | Desipramine Hcl | 12 | suppressed |
| Easy Touch Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Erythromycin | Erythromycin Base | 12 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Advair Hfa | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 11 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 11 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 11 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 11 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 11 | suppressed |
| Nikki | Ethinyl Estradiol/Drospirenone | 11 | suppressed |
| Triazolam | Triazolam | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $43.72 · 2 records | AstraZeneca Pharmaceuticals LP | BREZTRI, General - Pain Management | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error